Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE)
US7132432B2 · kind B2 · utility
0Cited by
7References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 2, 2004 |
| Grant date | Nov 7, 2006 |
| Priority date | — |
| Expiry date | May 27, 2025 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D413/14
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention provides compounds of Formula (I):or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein the variables L, Z0, R1, R4, R5, and R11 are defined are as defined herein, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-α converting enzyme (TACE), aggrecanase, or a combination thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.